Head and neck cancer articles within Nature Medicine

Featured

• Article | 24 August 2023

  Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

  Treatment of patients with metastatic salivary gland cancer with anti-PD-1 and anti-CTLA-4 led to encouraging clinical benefit in certain histologic subtypes, with translational analyses showing pre-existing T cell clonal expansion in responding tumors.

  • Joris L. Vos
  • , Bharat Burman
  •  & Luc G. T. Morris

• Article | 03 April 2023

  Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial

  In a phase 2 trial of pembrolizumab and cabozantinib in patients with advanced head and neck cancer, a high clinical benefit rate was achieved, which positively correlated with levels of CD8⁺ T cell infiltration but not tumor mutational burden.

  • Nabil F. Saba
  • , Conor E. Steuer
  •  & Christine H. Chung

• Article
  09 January 2023 | Open Access

  Autologous T cell therapy for MAGE-A4⁺ solid cancers in HLA-A*02⁺ patients: a phase 1 trial

  In a phase 1 dose-escalation trial in patients with nine different types of solid tumors, MAGE-A4-specific T cells had an acceptable safety profile and exhibited an encouraging overall response rate in patients with synovial sarcoma.

  • David S. Hong
  • , Brian A. Van Tine
  •  & Marcus O. Butler

• News & Views | 13 September 2021

  The expanding universe of checkpoint inhibitors for nasopharyngeal cancer

  Three phase 3 studies show that an immune-checkpoint inhibitor combined with chemotherapy improves progression-free survival in recurrent or metastatic nasopharyngeal cancer.

  • Brigette B. Y. Ma
  • , Edwin P. Hui
  •  & Anthony T. C. Chan

• Letter | 08 February 2021

  TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers

  In a first-in-human phase 1 trial of patients with HPV-associated metastatic epithelial cancers, T cells targeting HPV-16 E7 were well tolerated, with one observed dose-limiting toxicity, and elicited objective clinical responses in 6 of 12 treated patients.

  • Nisha B. Nagarsheth
  • , Scott M. Norberg
  •  & Christian S. Hinrichs

• Letter | 22 April 2019

  Immunogenic neoantigens derived from gene fusions stimulate T cell responses

  Fusion proteins in cancers with low mutational burden represent functional neoantigens that elicit T cell activation and mediate responses to immunotherapy.

  • Wei Yang
  • , Ken-Wing Lee
  •  & Luc G. T. Morris

• Technical Report | 01 June 2014

  On-demand intracellular amplification of chemoradiation with cancer-specific plasmonic nanobubbles

  Multidrug and radiation resistance, as well as nonspecific toxic effects of some drugs, currently limit some cancer therapies. Ekaterina Lukianova-Hleb and colleagues address this with the development of an intracellular drug release system using plasmonic nanobubbles for the on-demand release of the encapsulated payload from nanocarriers, achieving high target cell specificity and intracellular concentration and enhanced therapeutic efficacy of both drugs and X-rays. Validation is shown in aggressive and multidrug resistant head and neck squamous cell carcinoma using encapsulated doxorubicin and paclitaxel.

  • Ekaterina Y Lukianova-Hleb
  • , Xiaoyang Ren
  •  & Dmitri O Lapotko